Company to participate in 2026 Maxim Growth Summit (October 14) and Regional Biotechnology Conference (October 15)DOYLESTOWN, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that Oren Gilad PhD, President and CEO, will participate in the 2026 Maxim Growth Summit,
Company Strengthens Global Intellectual Property Portfolio with 28 Issued and 30 Pending Patents
This is the newest page. Registered accounts read further back.